Bone Marrow News and Research

RSS

Bone Marrow is the soft, sponge-like tissue in the center of most bones. It produces white blood cells, red blood cells, and platelets.

Kiadis Pharma receives FDA approval for IND to start pivotal clinical study for ATIR

Biopharmaceutical Company Kiadis Pharma announced today that it has received approval for its Investigational New Drug (IND) application with the US Food and Drug Administration (FDA) to start the pivotal clinical study for its product ATIR™ in the United States. Kiadis Pharma is currently enrolling patients in a multinational, pivotal clinical study at hospitals in Europe and Canada. With the approval of the IND, US hospitals will also participate in this study.

8 Jul 2010

Amniocentesis and non-embryonic stem cells among list of "Huge Medical Breakthroughs"

Two key focus areas of Biocell Center, the nation's first amniotic fluid stem cell bank, have been recently mentioned among the most important medical discoveries of the last century. Amniocentesis and non-embryonic stem cells were among the list of "Huge Medical Breakthroughs" presented in an article by Althea Chang on Mainstreet.com, produced by TheStreet.com on June 29, 2010.

8 Jul 2010

Study identifies factors that control production of HSCs

A team of researchers from the Institute for Research in Immunology and Cancer of the University of Montreal have made significant progress in the understanding of blood-producing (hematopoietic) stem cells. The study led by IRIC Chief Executive Officer and Scientific Director, Dr. Guy Sauvageau, identifies factors that control the production of hematopoietic stem cells.

7 Jul 2010

Aastrom to pursue Phase 3 CLI clinical program through FDA SPA process

Aastrom Biosciences, Inc., the leading developer of autologous cellular therapies for the treatment of severe cardiovascular diseases, today announced that the company will pursue a Phase 3 clinical program for its autologous cell therapy for the treatment of critical limb ischemia (CLI) through the U.S. Food and Drug Administration's special protocol assessment (SPA) process. Aastrom is currently completing a Phase 2b clinical trial of its cell therapy in patients with CLI and recently met with FDA officials to discuss plans for the Phase 3 program.

7 Jul 2010

Preclinical efficacy data of Sangamo's ZFN based human stem cell therapy for HIV published

Sangamo BioSciences, Inc. announced the publication of data demonstrating the preclinical efficacy of a human stem cell therapy for human immunodeficiency virus (HIV) based on its proprietary zinc finger DNA-binding protein nuclease (ZFN) technology.

6 Jul 2010

Pennsylvania Department of Health announces new study on blood disorder Polycythemia vera

The Pennsylvania Department of Health today announced a new, federally-funded study on the blood disorder Polycythemia vera, or PV, in Bedford, Blair, Cambria and Somerset counties.

3 Jul 2010

Heart patients treated for lymphoma at increased risk of cardiac problems

Older patients with Hodgkin lymphoma (HL) and a history of heart disease face a high risk of hospitalization for cardiac complications after completing treatment, according to research published online today in Blood, the journal of the American Society of Hematology. HL is a form of cancer of arising in the lymph nodes, and approximately 8,500 people were diagnosed with the disease in 2009, according to the American Cancer Society.

3 Jul 2010

Shire presents positive data from TKT-025 EXT Phase I/II study for VPRIV in type 1 Gaucher disease patients

Shire plc, the global specialty biopharmaceutical company, today announced positive data from its long-term extension to its open label Phase I/II study (TKT-025 EXT) for VPRIV® (velaglucerase alfa), the company's enzyme replacement therapy for patients with type 1 Gaucher disease. The data were presented at the 9th Annual European Working Group on Gaucher Disease (EWGGD) in Cologne, Germany, and add to the growing body of clinical evidence which supports the safety and sustained efficacy of VPRIV.

2 Jul 2010

Children's Hospital Boston researchers reprogram adult blood cells into iPS cells

In findings likely to make it easier and faster for stem cell biologists to generate patient-specific embryonic-like stem cells, researchers at Children's Hospital Boston have reprogrammed adult blood cells into induced pluripotent stem (iPS) cells.

2 Jul 2010

HL patients with heart disease at increased risk of hospitalization for cardiac complications after treatment

2 Jul 2010

Allogeneic stem cell transplant holds promise for treatment-resistant chronic lymphocytic leukemia

Allogeneic (donor-derived) stem cell transplant (alloSCT) may be a promising option for patients with treatment-resistant chronic lymphocytic leukemia (CLL), regardless of the patient's underlying genetic abnormalities, according to the results of a study published online today in Blood, the journal of the American Society of Hematology.

2 Jul 2010

Commonly used type of bone marrow stem cell may help treat sepsis, new study suggests

A new study from researchers in Ottawa and Toronto suggests that a commonly used type of bone marrow stem cell may be able to help treat sepsis, a deadly condition that can occur when an infection spreads throughout the body. The study, published in the American Journal of Respiratory and Critical Care Medicine, shows that these cells can triple survival rates in an experimental model of sepsis.

1 Jul 2010

New guide to get pregnant

Infertility affects about 7 million Americans -- that's about one in six couples during their childbearing years. There are many reasons for infertility, with equal chances it's his medical issue as it is hers. A new book, "A Baby at Last!: The Couples' Complete Guide to Getting Pregnant" (Fireside Books, Simon and Schuster), points the way for couples to get past the emotionally wrenching obstacle of infertility and finally bring home their bundle of joy.

1 Jul 2010

Eisai reports preliminary results from Dacogen for Injection Phase III study in AML

Eisai Inc. announced today preliminary results from a randomized Phase III clinical trial of Dacogen® (decitabine) for Injection versus either a low-dose chemotherapy agent or supportive care in elderly patients with acute myeloid leukemia (AML), a life-threatening cancer of the blood that generally occurs in older adults.

1 Jul 2010

SuperGen encouraged by Eisai's intent to file Dacogen sNDA for new indication

SuperGen, Inc., a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, announced that Eisai Inc. today released information regarding a randomized Phase III clinical trial of Dacogen® (decitabine) for Injection in elderly patients with acute myeloid leukemia (AML). The comparator in this trial was low-dose cytarabine, a chemotherapy agent, or supportive care.

30 Jun 2010

Threshold Pharmaceuticals commences TH-302 Phase 1 clinical trial in patients with advanced leukemias

Threshold Pharmaceuticals, Inc., today announced that it has initiated a Phase 1 clinical trial of TH-302 in patients with advanced leukemias. TH-302 is a proprietary Hypoxia-Activated Prodrug (HAP) that specifically targets tumor hypoxia.

29 Jun 2010

LEAPS vaccine technology generates dendritic cells to stimulate immune system to fight viral illnesses

CEL-SCI Corporation and researchers at the Northeastern Ohio Universities Colleges of Medicine and Pharmacy (NEOUCOM) jointly announced today that a LEAPS-based vaccine (Ligand Epitope Antigen Presentation System) study has demonstrated the technology's potential using dendritic cells to stimulate the immune system to fight viral illnesses and other diseases.

29 Jun 2010

FDA grants Tarix's TXA127 Orphan Drug designation for stem cell engraftment and treatment of MDS

Tarix Pharmaceuticals today announced that it's drug, TXA127, has been granted Orphan Drug designation from the U.S. Food and Drug Administration (FDA) as a treatment to enhance engraftment in patients receiving a stem cell transplant. TXA127 has also received Orphan Drug designation for the treatment of Myelodysplastic Syndrome (MDS).

28 Jun 2010

VPRIV receives positive opinion from CHMP for treatment of type 1 Gaucher disease

Shire plc, the global specialty biopharmaceutical company, announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion on the marketing authorisation for VPRIV (velaglucerase alfa), the company's enzyme replacement therapy for the treatment of type 1 Gaucher disease.

28 Jun 2010

Athersys, CSCRM and CWRU receive $1M to advance MultiStem therapy for SCI

Athersys, Inc. and its collaborators, including the Center for Stem Cell and Regenerative Medicine and Case Western Reserve University, announced today that they have been awarded $1 million through the Ohio Third Frontier Biomedical Program to support research into the treatment of spinal cord injury with MultiStem, Athersys' proprietary stem cell product candidate.

25 Jun 2010

Bone Marrow News and Research

Further Reading

Kiadis Pharma receives FDA approval for IND to start pivotal clinical study for ATIR

Amniocentesis and non-embryonic stem cells among list of "Huge Medical Breakthroughs"

Study identifies factors that control production of HSCs

Aastrom to pursue Phase 3 CLI clinical program through FDA SPA process

Preclinical efficacy data of Sangamo's ZFN based human stem cell therapy for HIV published

Pennsylvania Department of Health announces new study on blood disorder Polycythemia vera

Heart patients treated for lymphoma at increased risk of cardiac problems

Shire presents positive data from TKT-025 EXT Phase I/II study for VPRIV in type 1 Gaucher disease patients

Children's Hospital Boston researchers reprogram adult blood cells into iPS cells

HL patients with heart disease at increased risk of hospitalization for cardiac complications after treatment

Allogeneic stem cell transplant holds promise for treatment-resistant chronic lymphocytic leukemia

Commonly used type of bone marrow stem cell may help treat sepsis, new study suggests

New guide to get pregnant

Eisai reports preliminary results from Dacogen for Injection Phase III study in AML

SuperGen encouraged by Eisai's intent to file Dacogen sNDA for new indication

Threshold Pharmaceuticals commences TH-302 Phase 1 clinical trial in patients with advanced leukemias

LEAPS vaccine technology generates dendritic cells to stimulate immune system to fight viral illnesses

FDA grants Tarix's TXA127 Orphan Drug designation for stem cell engraftment and treatment of MDS

VPRIV receives positive opinion from CHMP for treatment of type 1 Gaucher disease

Athersys, CSCRM and CWRU receive $1M to advance MultiStem therapy for SCI

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Sensing a Healthier Future

Latest News